ArticleInfection and drug resistance2026
The Outcome of Tuberculosis Treatment in the Presence of SARS-CoV-2 Anti-RBD Antibody.
Article in Infection and drug resistance, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Vaccination or infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) can induce specific antibodies. The level of anti-spike receptor-binding (RBD) antibody may last long and interact with the immune response to tuberculosis (TB). We aimed to investigate the impact of the anti-RBD antibody level at baseline on the outcome of the intensive phase of TB treatment. Patients and Methods: This cohort study recruited newly diagnosed TB patients from September 2022 to May 2023. Observation was conducted at baseline and after two months of TB treatment. Interviews and physical examinations were performed for patients with a history of Coronavirus Disease 2019 (COVID-19) vaccination or infection and anthropometric data, respectively. Peripheral blood was collected for baseline assessment of anti-RBD antibodies, an interferon gamma release assay (IGRA), and complete blood count. The clinical outcomes of TB treatment include sputum conversion, hematology parameters and body mass index (BMI). Results: Among the 63 participants, the majority were vaccinated for COVID-19 (73,02%), underweight (58.73%), and IGRA positive (79,03%), increased median ESR (71.5 (IQR 18-111) mm/hour), and slightly low median lymphocyte proportion (19.5 (IQR 7-33) %) at baseline. The median titer of anti-RBD antibodies at baseline was 1,584.2 (IQR 95.6-34,379.3) AU/mL/. At two months of TB treatment, all the returned participants had sputum conversion and improved BMI and normal hematology parameters. The anti-RBD antibody level was associated with the baseline BMI (β Conclusion: Our study revealed that susceptible TB patients had favorable outcomes after 2 months of TB treatment when baseline anti-RBD antibody was high at baseline. We suggest that larger studies are needed to confirm the relationship.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.